Introduction
============

In the last two decades, scientists around the globe paid increasing attention toward UPS, a primary pathway for regulation of protein turnover and removal of misfolded proteins in eukaryotic cells. The molecular mechanism of proteasomal protein degradation is driven by a consecutive action of three enzyme categories (E1 activating, E2 conjugating, and E3 ligating) that covalently tag substrate proteins with a chain of ubiquitins, small regulatory proteins ([@B34]; [@B58]). Subsequent fate of the substrate is defined depending on type of ubiquitin linkage, its length and post-translational modifications. UPS operates in nucleus and cytoplasm, which enables ubiquitin-mediated regulation of cell cycle control, DNA damage response, innate immunity, and proteasomal protein degradation.

E3 ligases confer substrate specificity of the whole UPS and function via two primary mechanisms -- they can play an intermediary catalytic role in transfer of ubiquitins from E2∼Ub conjugate to the substrate or, alternatively, facilitate direct ubiquitin transfer bypassing the E3 ligase itself. The first mechanism is common for Homologous to E6-AP Carboxy Terminus (HECT)-type E3s, whereas the second one is typical for RING-type E3s.

Initially the RING domain was identified in RING1 protein and later confirmed to be a structural element of Rbx1 that functions as E2-recruiting subunit of E3 ligase ([@B40]; [@B53]; [@B64]; [@B72]). The canonical RING finger motif can be represented as Cys-X~2~-Cys-X~(9-39)~-Cys-X~(1-3)~-His-X~(2-3)~-Cys-X~2~-Cys-X~(4-48)~-Cys-X~2~-Cys, where X is any other amino acid ([@B19]). The domain includes two Zn^2+^-coordinated loops and intervening central α-helix that together form a conserved structural platform for anchoring the E2 conjugating enzyme.

RING E3s can be categorized according to the form of subunit organization: (1) mono-subunit ligases like MDM and Cbl; (2) multi-subunit complexes such as CRL, anaphase promoting complex/cyclosome (APC/C) ([@B12]) and FANC ([@B48]). Another important RING family members are RBRs, the single subunit enzymes with multiple RING domains ([@B69]). In addition, worth mentioning are U-box ligases, containing atypical RING domains without coordinated Zn^2+^ ions, that are often featured as separate from canonical RING E3s ([@B31]).

Notably, E3 ligases were proposed to become the "new kinases" owing to the significant therapeutic and market potential of their small molecule inhibitors ([@B17]). Recent advances demonstrated that E3s in general, and MDM and Cullin families (**Figures [1A,B](#F1){ref-type="fig"}**), in particular, have captured significant attention of the research community due to their key role in poly-ubiquitination of substrate proteins ([@B47]).

![Structural organization of **(A)** MDM and **(B)** CRL RING-type E3 ubiquitin ligases and a brief list of their most potent modulators. MDM2 and MDM4 are single subunit proteins containing C-terminal RING finger domain. In contrast, CRLs are constituted of several subunits, such as receptor, adaptor, Cullin scaffold and RING-box protein. **(C)** Schematic representation of PROTAC/SNIPER molecule acting to induce ubiquitination and subsequent proteasomal degradation of substrate protein of interest. These small molecule degraders contain substrate-specific component, short linker, and E3-specific component.](fphar-09-00450-g001){#F1}

Here, we briefly highlight members of MDM and CRL families of RING-type E3 ligases, their primary functions and small molecule modulation.

MDM Family -- MDM2 and MDM4
===========================

MDM family includes MDM2 and its homolog MDM4 (also known as MDMX). Both enzymes are overexpressed in many cancers and function as key negative regulators of oncosuppressor protein p53 that is often referred to as "guardian of the genome" ([@B32]). MDM2-MDM4-p53 signaling circuit regulates core metabolic pathways that involve DNA damage response, induction of apoptosis, cell cycle arrest, and senescence. In nearly half of cancers p53 is downregulated due to overexpression of MDM2 or/and MDM4, while the other half is caused by tumorigenic missense mutations of p53, mostly occurring in DNA-binding domain ([@B49]).

MDM2 binds wild-type p53 with high affinity, blocks its transcriptional activator functions and regulates its nuclear export, stability, intracellular levels ([@B29]). MDM4 shares a high structural homology with MDM2, mainly in the N-terminal p53-binding domain, yet due to low E3 ligase activity its overexpression does not lead to dramatic p53 downregulation ([@B37]). Interaction of MDM2 and MDM4 via their RING domains results in formation of MDM2/MDM4 hetero-dimeric complex that enhances p53 ubiquitination and degradation ([@B55]).

Many therapeutic strategies based on disrupting p53/MDM2 protein--protein interaction are aimed to stabilize and activate p53 in order to initiate programmed cell death in cancers with overexpressed MDM2 ([@B82]). Numerous examples of MDM2 inhibitors include small synthetic molecules such as Nutlin-3a ([@B76]), RG7112 ([@B77]), NU8231 ([@B30]), MI773 ([@B83]), CGM097 ([@B35]) with several others already in clinical trials as drug candidates ([@B74]) (**Figure [1A](#F1){ref-type="fig"}**). Development of potent MDM2 inhibitors remains a longstanding mainstream in the p53 field, meanwhile the importance of therapeutic targeting MDM4 was recognized later. To date a certain progress was achieved in development of p53/MDM4 inhibitors such as SJ-172550 ([@B61]; [@B3]), WK298 ([@B59]) and stabilized peptide SAH-p53-c8 ([@B2]).

In addition, simultaneous inhibition of both MDM2 and MDM4 enzymes, i.e., by means of dual inhibitors, was proposed to enhance p53 activation ([@B36]; [@B59]; [@B80]). Stapled peptide ALRN-6924 (Aileron, Inc.) is an example of dual inhibitor that is currently undergoing clinical trials against solid tumors and lymphomas ([@B15]). Also, worth mentioning an approach based on targeting MDM2/MDM4 interface with short peptides that initiate p53-induced apoptosis and slowdown of tumor growth ([@B56]).

Cullin Family -- Cullin Ring E3 Ligases (CRLs)
==============================================

Cullin RING E3 ligases constitute the largest family of E3 ligases with over 200 known members ([@B62]). In certain cell types up to 20% of the proteasomal protein degradation is mediated by CRLs ([@B68]). Classification of CRL family is based on type of Cullin scaffold serving as a backbone of the multi-subunit protein complex. The evolutionary conserved Cullin protein has several forms that share structural similarity -- Cul1, Cul2, Cul3, Cul4A, Cul4B, Cul5, and Cul7. Accordingly, the resulting E3 ligases are named CRL1-CRL7. Some classifications also include Cul9 known as p53-associated parkin-like cytoplasmic protein (PARC) ([@B44]).

Assembly of the multi-subunit CRLs was originally reported for the archetypal Skp1-Cul1-Rbx1 complex ([@B22]). The CRL structure is based on modular organization of constituent subunits such as substrate receptors (F-box, SOCS-box, DCAF, and BTB), adaptors (Skp1, ElonginB, ElonginC, DDB1, and BTB), Cullin scaffolds (Cul1-Cul7 and Cul9) and RING finger proteins (Rbx1 and Rbx2). The wide range of building blocks and their combinations enables formation of a multitude of functionally diverse E3 ligases ([@B5]; [@B62]; [@B46]). Full-size CRLs are notoriously difficult to obtain and characterize, to date only several complexes containing a complete set of subunits were reported, including SOCS2-EloB-EloC-Cul5-Rbx2 ([@B9]), VHL-EloB-EloC-Cul5-Rbx1 ([@B10]), Skp2-Skp1-Cul1-Rbx1 ([@B85]), DDB2-DDB1-Cul4A-Rbx1 ([@B24]).

Drug discovery in the CRL field keeps advancing, driven by foreseeable role of these enzymes as targets in numerous human diseases ([@B57]; [@B17]; [@B1]; [@B84]). The CRLs as drug targets are promising, yet highly sophisticated due to diverse putative combinations of structural components that result in multiple protein--protein interfaces.

The growing number of reported CRL crystal structures includes full-size enzymes, individual components and their complexes. Here, particularly important are structures of receptor subunits with bound small molecules because they provide crucial information for rational design of potent modulators. Examples (**Figure [1B](#F1){ref-type="fig"}**) include Probe 8, auxin-mimic that disrupts interaction between TIR1 (receptor in CRL1^TIR1^) and its substrate Aux/IAA ([@B33]); VL111, Ligand 7 and their enhanced analog VH298 that inhibit binding of VHL protein (receptor in CRL2^VHL^) to substrate hypoxia-inducible factor 1-alpha (HIF1α) ([@B7]; [@B28]; [@B67]); thalidomide and its derivatives lenalidomide, pomalidomide that modulate CRL4A^CRBN^ activity by binding to its CRBN receptor subunit ([@B13]; [@B23]).

Targeting CRLs for therapeutic applications is obstructed by several factors. Firstly, there is no general approach and each enzyme has to be tackled individually according to its structural and functional characteristics. Secondly, CRLs are complex molecular entities assembled from several independent subunits that form a number of protein--protein interfaces and druggable pockets. Surprisingly, the apparent complexity of this multi-subunit system might turn out to be an advantage -- the multitude of interfaces and pockets provides additional opportunities for design of specific binders ([@B8]). Small molecules modulate CRL activity directly by inhibiting substrate/receptor interaction, disrupting CRL assembly, inducing allosteric conformational shifts that lead to suppressed activity or altered ensemble dynamics ([@B43]). In some cases modulators stabilize specific protein--protein interactions within the CRL complex ([@B73]).

Ring-Type E3 Ligases as Targets for Drug Discovery
==================================================

Drug discovery in the UPS field thrived since FDA approval of 26S proteasome inhibitors Bortezomib (approved in 2003, marketed as Velcade^®^) and more recently Carfilzomib (approved in 2012, marketed as Kyprolis^®^) for treatment of multiple myeloma. Although proteasome inhibitors demonstrate selectivity toward tumor cells and lead to apoptosis, they also suppress proteasome-mediated degradation of all intracellular proteins resulting in potential side effects ([@B66]). In addition to that, many patients were demonstrated to develop resistance toward Bortezomib that acts as a reversible competitive inhibitor of 26S proteasome ([@B52]). Strategies to overcome the resistance include design of inhibitors with alternative mechanism of action, i.e., Carfilzomib covalently binds proteasome and causes its irreversible inhibition.

Another emerging and highly promising strategy is to target different levels of ubiquitination cascade upstream of proteasome, mainly E1, E2, and E3 enzymes ([@B65]). Here, E3 ligases determine substrate specificity and, therefore, represent primary molecular targets for small molecule modulation. Development of potent E3 ligase modulators is risky and challenging task complicated by diverse protein--protein interfaces of the multi-component complexes, lack of a classical enzymatic/catalytic active site and specificity problems stipulated by a variety of potential substrates.

RING-type E3 ligases were previously successfully targeted using small molecule inhibitors of protein--protein interactions, i.e., binding at substrate/receptor HIF1α/VHL ([@B51]), p53/MDM2 and p53/MDM4 interfaces ([@B50]), adaptor/receptor interface Skp1/Skp2 ([@B16]) and several other, as reviewed in [@B8].

In addition, it would be reasonable to mention an auxiliary protein NEDD8 that serves as crucial regulator of CRL functions ([@B68]). The ubiquitin-like protein NEDD8 gets covalently conjugated to a specific conserved lysine residue at C-terminal domain of Cullin scaffold in a process termed NEDDylation. NEDD8 conjugation enhances substrate ubiquitination by promoting CRL dynamics and inducing conformational shift of the protein ensemble that brings together E3-bound substrate and Rbx--E2∼Ub ([@B20], [@B21]). In addition, MDM2 was demonstrated not only to autoNEDDylate itself, but also to mediate p53 NEDDylation that inhibits its transcriptional activity ([@B79]). Pevonedistat (also known as MLN4924), a first-in-class selective inhibitor of NEDD8-activating enzyme (NAE) that mediates NEDDylation, is currently undergoing several clinical trials against different types of cancer ([@B71]).

Targeted Protein Degradation Mediated by Ring-Type E3 Ligases
=============================================================

A novel paradigm-shifting approach that dramatically increases the attractiveness of E3 ligases as targets for drug design is based on proteolysis-targeting chimeras (PROTACs) ([@B6]; [@B41]). These are hetero-bifunctional compounds with bivalent selectivity, they consist of three key elements: substrate-specific component ("warhead"), short linker, and E3-specific component. PROTACs bind and bring into close proximity substrate protein of interest (POI) and E3 ligase thus facilitating E3-mediated ubiquitination of the substrate (**Figure [1C](#F1){ref-type="fig"}**). This approach, sometimes called as "chemical knockdown," enables ligand-induced degradation of specific endogenous proteins ([@B4]).

Historically the first small-molecule-based PROTAC degrader was developed for recruiting MDM2 E3 ligase by Nutlin-3a imidazoline derivative, as reported by Crews laboratory ([@B63]). In this study androgen receptor (AR) was targeted by SARM compound connected to Nutlin-3a moiety via PEG-based linker. Treatment of AR-expressing HeLa cells with SARM-Nutlin-3a bivalent molecule resulted in depletion of AR levels. Since then there were no subsequent reports of MDM2-mediated PROTACs, though given the large and still expanding repertoire of potent MDM2 inhibitors it would be reasonable to expect much higher interest in such degraders.

CRL2^VHL^ is the most prominent example of E3 ligase directed by PROTACs to ubiquitinate a recruited substrate protein and result in its proteasomal degradation. The E3-specific component is designed to mimic HIF1α, natural substrate of VHL receptor, post-translationally hydroxylated at prolines 402 and/or 564. Examples of proteins selectively targeted by PROTACs via CRL2^VHL^-mediated mechanism include BET family of epigenetic regulators BRD2, BRD3, and BRD4 ([@B81]; [@B60]; [@B27]; [@B86]; [@B14]), steroid hormone receptor ERRα and serine-threonine kinase RIPK2 ([@B4]). Another recent study demonstrated successful degradation of oncogenic tyrosine kinase BCR-ABL using both CRL2^VHL^- and CRL4A^CRBN^-specific PROTACs ([@B42]). Here, FDA-approved tyrosine kinase inhibitors Bosutinib and Dasatinib served as PROTAC "warheads," whereas hydroxy-proline derivative and pomalidomide were used as CRL2^VHL^- and CRL4A^CRBN^-binding components, respectively. Similarly, PROTAC-directed CRL4A^CRBN^-mediated target degradation also includes BRD4 and cytosolic protein FKBP12 ([@B45]; [@B78]). In addition, Ciulli laboratory recently reported curious example of the first homo-bivalent PROTAC (Homo-PROTAC) that simultaneously recruits two CRL2^VHL^ molecules and induces their suicidal self-degradation ([@B47]). Highly potent Homo-PROTAC CM11 contains two molecules of the previously described VH298 compound connected via polyethylene glycol linker ([@B25]; [@B67]).

SNIPERs, an abbreviated form of specific and non-genetic IAP-dependent protein erasers, are a class of small-molecule degraders similar to PROTACs ([@B38], [@B39]). These compounds recruit IAP family of RING-type E3 ligases -- cIAP1, cIAP2, and XIAP. The SNIPER chemical structure consists of selective IAP antagonist (i.e., Bestatin, MV1, and LCL161), PEG linker and peptide- or small-molecule-based POI-specific component. The initial concept was further explored by Naito laboratory that recently demonstrated selective proteasomal degradation of a range of substrate proteins, including ERα ([@B52]), BCR-ABL ([@B65]), BRD4 and PDE4 ([@B51]), NOTCH1 ([@B50]), CRABP-II ([@B54]).

These examples, listed in **Table [1](#T1){ref-type="table"}**, illustrate that induced protein depletion mediated by small molecule degraders (PROTACs and SNIPERs) specific for certain RING-type E3 ligases (MDMs, CRLs, and IAPs) is a justified paradigm for drug discovery. These compounds operate in sub-stoichiometric manner and catalyze enzymatic removal of substrate POIs (chemical knockdown) rather than their inhibition via binding site occupation. The PROTAC/SNIPER-based approach counteracts restoration of intracellular POI levels and is seen as a promising addition to conventional gene knockdown techniques (i.e., RNAi, antisense oligonucleotides, and CRISPR/Cas9) ([@B18]).

###### 

List of substrate proteins targeted by PROTACs and SNIPERs for RING-type E3-mediated proteasomal degradation.

  Substrate          RING-type E3 ligase      Reference
  ------------------ ------------------------ ----------------------------------------
  **PROTACs**                                 
  AR                 MDM2                     [@B63]
  BRD2, BRD3, BRD4   CRL2^VHL^                [@B73]; [@B81]; [@B60]; [@B27]; [@B14]
  ERRα, RIPK2        CRL2^VHL^                [@B4]
  VHL                CRL2^VHL^                [@B47]
  BCR-ABL            CRL2^VHL^, CRL4A^CRBN^   [@B42]
  FKBP12             CRL4A^CRBN^              [@B78]
  BRD4               CRL4A^CRBN^              [@B45]; [@B78]
  **SNIPERs**                                 
  AR                 cIAP1/cIAP2/XIAP         [@B66]
  ERα                                         [@B52]
  BCR-ABL                                     [@B65]
  BRD4                                        [@B51]
  PDE4                                        [@B51]
  NOTCH1                                      [@B50]
  CRABP-II                                    [@B54]
                                              

Conclusion
==========

Many E3 ubiquitin ligases are implicated in cellular physiology and homeostasis at multiple regulatory levels, play crucial roles in a wide range of human diseases, including cancer and inflammatory disorders. The RING-type ligases represent the largest class of E3s in humans and are responsible for recognition, poly-ubiquitination and subsequent proteasomal degradation of numerous substrate proteins. Given the structural intricacy of RING-type E3s and their diverse functions it is essential to understand molecular principles that govern assembly and interactions of subunits within the protein complex. We anticipate a forthcoming re-focusing of research efforts from structural/functional characterization of these enzymes to rational design of precision molecular tools capable of modulating E3 activity in living cells and organisms. One could envisage that targeted therapeutic action upstream of proteasome could potentially lead to emerging resistance caused by feedback-driven compensatory mechanisms. This could potentially be overcome by administering a synergistic combination of drugs that act via distinct molecular mechanisms.

The MDM and CRL families of RING-type E3s are growing in importance as attractive targets for small molecule therapeutics that could operate not only as inhibitors but also activators of enzymatic activity, disruptors and stabilizers of protein--protein interactions, regulators of protein dynamics. The availability of X-ray structural data, especially for full-size enzymes, remains to be one the main limitations for structure-based design of modulators for multi-subunit E3 complexes. Nevertheless, slow yet steady increase of solved crystal structures of RING-type E3s and their ligand-bound complexes provides opportunities for further rational design of highly potent modulators. General strategies for discovery of novel E3 modulators include *in vitro* screening of compound libraries using functional assays (i.e., ubiquitination assay) ([@B70]); software packages (i.e., ICM-Pocket Finder) predicting druggable pockets for subsequent *in silico* ligand screening and docking ([@B11]); fragment-based discovery and rational structure elaboration ([@B75]; [@B26]).

In addition, PROTAC/SNIPER-induced ubiquitination and intracellular degradation of specific substrates offers an added layer of specificity and constitutes an emerging strategy for post-translational regulation of protein levels. These compounds demonstrate high potential for a novel modality of chemical intervention on UPS and hold much promise as prospective therapeutic candidates. Such chemical protein knockdown technologies based on RING-type E3 modulation still remain largely untapped by the pharmaceutical industry, however, it is reasonable to expect a major progress in this direction in near future.
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ABL

:   Abelson tyrosine-protein kinase

AR

:   androgen receptor

BCR

:   breakpoint cluster region protein

BET

:   bromodomain and extra-terminal domain

BRD2

:   bromodomain-containing protein 2

cIAP1

:   cellular inhibitor of apoptosis protein 1

CRABP-II

:   cellular retinoic acid binding protein-II

CRL

:   cullin RING E3 ligase

ERα

:   estrogen receptor α

FANC

:   Fanconi anemia ligase

HIF1α

:   hypoxia-induced factor 1-α

IAP

:   inhibitor of apoptosis protein

MDM2

:   murine double minute 2

NAE

:   NEDD8-activating enzyme

NEDD8

:   neural precursor cell expressed developmentally down-regulated protein 8

NOTCH1

:   neurogenic locus notch homolog protein 1

PDE4

:   cAMP-specific 3′,5′-cyclic phosphodiesterase 4

POI

:   protein of interest

PROTAC

:   proteolysis-targeting chimera

RBR

:   RING-between RING-RING

RING

:   really interesting new gene

SARM

:   selective androgen receptor modulator

SNIPER

:   specific and non-genetic IAP-dependent protein erasers

UPS

:   ubiquitin--proteasome system

VHL

:   von Hippel-Lindau

XIAP

:   X-linked inhibitor of apoptosis protein
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